Event Details
Wednesday, November 12, 2025
1:00 PM – 2:00 PM ET
12:00 PM – 1:00 PM
CT
11:00 AM – 12:00 PM MT
10:00 AM – 11:00 AM PT
Format
Live Interactive Webinar
Target Audience
This activity is intended
for hematologists-oncologists, medical oncologists, PAs, NPs, nurses, and
other healthcare professionals engaged in the care of patients
with Chronic Lymphocytic Leukemia (CLL).
Description
This webinar will provide a clinical
update on chronic lymphocytic leukemia (CLL). Expert faculty will review the
latest therapies, including BTK inhibitors and CAR T-cell therapy, share
guidance on patient selection, and discuss strategies for treatment
management, toxicity monitoring, and long-term survivorship care.
Learning Objectives
After completing this activity, the participant should be better able
to:
- Explain treatment options including an overview of the latest developments in therapy
- Identify patients who are candidates for newly approved therapies including BTK inhibitors, alone or in combination, and CAR T-cell therapy
- Explain the HCP’s role in preparing the patient for therapy, administering treatment, monitoring for and managing side effects
- Discuss long-term follow up and survivorship care planning
Faculty
Inhye Ahn, MD
Associate
Director, Chronic Lymphocytic Leukemia Center
Senior Physician
Assistant
Professor of Medicine, Harvard Medical School
Dana-Farber Cancer
Institute
Boston, MA
Lauren Berger, MPH
Blood Cancer United
Washington,
DC
Corinne Hoffman, MS, APRN-CNP, AOCNP
Nurse Practitioner
- Hematology Oncology
The James Comprehensive Cancer Center
The Ohio
State University
Columbus, OH
Kerry Rogers, MD
Associate Professor
Division
of Hematology, Department of Internal Medicine
The James Comprehensive
Cancer Center
The Ohio State University
Columbus, OH
Continuing Education Information
In support of improving patient care, this activity has been planned and
implemented by Blood Cancer United and Medical Learning Institute Inc.
Medical Learning Institute Inc is jointly accredited by the
Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Physician Continuing Medical Education
Medical Learning
Institute, Inc. (MLI) designates this live activity for a maximum of
1.0 AMA PRA Category 1 Credits™.
Physicians should
claim only the credit commensurate with the extent of their participation in
the activity.
Registered Nursing Credit Designation
Approval for
nurses has been obtained by the National Office of Blood Cancer United under
Provider Number CEP 5832 to award 1.0 continuing education contact hour
through the California Board of Registered Nursing.
Method of Participation
There are no fees for
participating in or receiving credits for this CE activity. For information on
applicability and acceptance of continuing education credit for this activity,
please consult your professional licensing board.
Learners must participate in the entire CE activity, complete, and submit the evaluation form to earn credit. Once submitted, the certificate will be generated. If you have questions regarding the receipt of your certificate, please contact via email at [email protected].
Providers
This activity is provided by Blood Cancer United and Medical Learning Institute Inc.
Supporters
This activity is supported by independent medical education grants from AbbVie Inc. and AstraZeneca Pharmaceuticals.
For questions, concerns, or assistance for people with disabilities or grievances, please contact us at: [email protected].